AstraZeneca Opts for Regulatory Flexibility
Executive Summary
Pharmaceutical companies often pursue the more flexible Mutual Recognition Procedure over the rigid centralized process when applying for marketing authorization in Europe. They're right to do so-as AstraZeneca's recent experience with Crestor shows, even when the MRP's flexibility gets in the way of Europe-wide approvals, the process can be safer than the alternative.